Titre :

Thiotepa-based regimens are a valid alternative to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT.

Auteur(s) :

Battipaglia, Giorgia [Auteur]
University of Naples Federico II = Università degli studi di Napoli Federico II
Labopin, Myriam [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
CHU Saint-Antoine [AP-HP]
Mielke, Stephan [Auteur]
Karolinska University Hospital [Stockholm]
Ruggeri, Annalisa [Auteur]
Ospedale San Raffaele
Ozkurt, Zubeyde Nur [Auteur]
Gazi University
Bourhis, Jean Henri [Auteur]
Institut Gustave Roussy [IGR]
Rabitsch, Werner [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Grillo, Giovanni [Auteur]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Arcese, William [Auteur]
Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
Novis, Yana [Auteur]
Fegueux, Nathalie [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Spyridonidis, Alexandros [Auteur]
General University Hospital of Patras
Giebel, Sebastian [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Ciceri, Fabio [Auteur]
Ospedale San Raffaele
Mohty, Mohamad [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
CHU Saint-Antoine [AP-HP]

Titre de la revue :

Transplantation and Cellular Therapy

Nom court de la revue :

Transplant Cell Ther

Date de publication :

2023-10-12

ISSN :

2666-6367

Résumé en anglais : [en]

Total body irradiation (TBI) at myeloablative doses is superior to chemotherapy-based regimens in young patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation ...
Lire la suite >Total body irradiation (TBI) at myeloablative doses is superior to chemotherapy-based regimens in young patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, in elderly and unfit patients, in whom reduced-intensity conditioning (RIC) regimens are preferred, whether a TBI-based or a chemotherapy-based approach is better is unexplored. Thiotepa can be used as part of ALL conditioning regimens. The current study aimed to compare transplantation outcomes after RIC with TBI-based or thiotepa-based regimens in patients with ALL. The study cohort comprised patients aged ≥40 years undergoing allo-HSCT for ALL in first complete remission between 2000 and 2020 who received an RIC regimen containing either TBI (4 to 6 Gy) or thiotepa. We identified a total of 265 patients, including 117 who received a TBI-based RIC regimen and 148 who received a thiotepa-based RIC regimen. Univariate analysis revealed no significant differences in the following transplantation outcomes for TBI versus thiotepa: relapse, 23% versus 28% (P = .24); nonrelapse mortality, 20% versus 26% (P = .61); leukemia-free survival, 57% versus 46% (P = .12); overall survival, 67% versus 56% (P = .18); graft-versus-host disease (GVHD]/relapse-free survival, 45% versus 38% (P = .21); grade II-IV acute GVHD, 30% in both groups (P = .84); grade III-IV acute GVHD, 9% versus 10% (P = .89). The sole exception was the incidence of chronic GVHD, which was higher in the recipients of TBI-based regimens (43% versus 29%; P = .03). However, multivariate analysis revealed no differences in transplantation outcomes between the 2 groups. In patients aged ≥40 years receiving RIC, use of a thiotepa-based regimen may represent a valid alternative to TBI-based regimens, as no differences were observed in the main transplantation outcomes.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-02-06T22:25:33Z
2024-03-15T10:37:34Z